-
1
-
-
0031720795
-
Is type II diabetes mellitus a disease of the innate immune system?
-
Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 1998; 41: 1241-1248.
-
(1998)
Diabetologia
, vol.41
, pp. 1241-1248
-
-
Pickup, J.C.1
Crook, M.A.2
-
2
-
-
0030731621
-
NIDDM as a disease of the innate immune system: association of acute- phase reactants and interleukin-6 with metabolic syndrome X
-
Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute- phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997; 40: 1286-1292.
-
(1997)
Diabetologia
, vol.40
, pp. 1286-1292
-
-
Pickup, J.C.1
Mattock, M.B.2
Chusney, G.D.3
Burt, D.4
-
3
-
-
0345700727
-
Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study
-
Spranger J, Kroke A, Mohlig M et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003; 52: 812-817.
-
(2003)
Diabetes
, vol.52
, pp. 812-817
-
-
Spranger, J.1
Kroke, A.2
Mohlig, M.3
-
4
-
-
0035908632
-
C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus
-
Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 327-334.
-
(2001)
JAMA
, vol.286
, pp. 327-334
-
-
Pradhan, A.D.1
Manson, J.E.2
Rifai, N.3
Buring, J.E.4
Ridker, P.M.5
-
5
-
-
0027459878
-
Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance
-
Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.
-
(1993)
Science
, vol.259
, pp. 87-91
-
-
Hotamisligil, G.S.1
Shargill, N.S.2
Spiegelman, B.M.3
-
6
-
-
0036738398
-
Glucose-induced beta-cell production of interleukin-1beta contributes to glucotoxicity in human pancreatic islets
-
Maedler K, Sergeev P, Ris F et al. Glucose-induced beta-cell production of interleukin-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002; 110: 851-860.
-
(2002)
J Clin Invest
, vol.110
, pp. 851-860
-
-
Maedler, K.1
Sergeev, P.2
Ris, F.3
-
7
-
-
0025177196
-
Elevation of C-reactive protein in active coronary artery disease
-
Berk BC, Weintraub WS, Alexander RW. Elevation of C-reactive protein in active coronary artery disease. Am J Cardiol 1990; 65: 168-172.
-
(1990)
Am J Cardiol
, vol.65
, pp. 168-172
-
-
Berk, B.C.1
Weintraub, W.S.2
Alexander, R.W.3
-
8
-
-
40449113524
-
The role of inflammatory cytokines in diabetic nephropathy
-
Navarro-Gonzalez JF, Mora-Fernandez C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 2008; 19: 433-442.
-
(2008)
J Am Soc Nephrol
, vol.19
, pp. 433-442
-
-
Navarro-Gonzalez, J.F.1
Mora-Fernandez, C.2
-
9
-
-
34548431826
-
Increased number of islet-associated macrophages in type 2 diabetes
-
Ehses JA, Perren A, Eppler E et al. Increased number of islet-associated macrophages in type 2 diabetes. Diabetes 2007; 56: 2356-2370.
-
(2007)
Diabetes
, vol.56
, pp. 2356-2370
-
-
Ehses, J.A.1
Perren, A.2
Eppler, E.3
-
10
-
-
71949118923
-
Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I
-
Boni-Schnetzler M, Boller S, Debray S et al. Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I. Endocrinology 2009; 150: 5218-5229.
-
(2009)
Endocrinology
, vol.150
, pp. 5218-5229
-
-
Boni-Schnetzler, M.1
Boller, S.2
Debray, S.3
-
11
-
-
77955492173
-
Toll-like receptor 2-deficient mice are protected from insulin resistance and beta cell dysfunction induced by a high-fat diet
-
Ehses JA, Meier DT, Wueest S et al. Toll-like receptor 2-deficient mice are protected from insulin resistance and beta cell dysfunction induced by a high-fat diet. Diabetologia 2010; 53: 1795-1806.
-
(2010)
Diabetologia
, vol.53
, pp. 1795-1806
-
-
Ehses, J.A.1
Meier, D.T.2
Wueest, S.3
-
12
-
-
75649096002
-
Thioredoxin-interacting protein links oxidative stress to inflammasome activation
-
Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 2010; 11: 136-140.
-
(2010)
Nat Immunol
, vol.11
, pp. 136-140
-
-
Zhou, R.1
Tardivel, A.2
Thorens, B.3
Choi, I.4
Tschopp, J.5
-
13
-
-
77951800951
-
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
-
Duewell P, Kono H, Rayner KJ et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010; 464: 1357-1361.
-
(2010)
Nature
, vol.464
, pp. 1357-1361
-
-
Duewell, P.1
Kono, H.2
Rayner, K.J.3
-
14
-
-
32944468985
-
Gout-associated uric acid crystals activate the NALP3 inflammasome
-
Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440: 237-241.
-
(2006)
Nature
, vol.440
, pp. 237-241
-
-
Martinon, F.1
Petrilli, V.2
Mayor, A.3
Tardivel, A.4
Tschopp, J.5
-
15
-
-
79955038882
-
Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling
-
Wen H, Gris D, Lei Y et al. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat Immunol 2011; 12: 408-415.
-
(2011)
Nat Immunol
, vol.12
, pp. 408-415
-
-
Wen, H.1
Gris, D.2
Lei, Y.3
-
16
-
-
79751512463
-
The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance
-
Vandanmagsar B, Youm YH, Ravussin A et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 2011; 17: 179-188.
-
(2011)
Nat Med
, vol.17
, pp. 179-188
-
-
Vandanmagsar, B.1
Youm, Y.H.2
Ravussin, A.3
-
17
-
-
0029979369
-
Biologic basis for interleukin-1 in disease
-
Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87: 2095-2147.
-
(1996)
Blood
, vol.87
, pp. 2095-2147
-
-
Dinarello, C.A.1
-
18
-
-
77956958947
-
Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes
-
Masters SL, Dunne A, Subramanian SL et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes. Nat Immunol 2010; 11: 897-904.
-
(2010)
Nat Immunol
, vol.11
, pp. 897-904
-
-
Masters, S.L.1
Dunne, A.2
Subramanian, S.L.3
-
19
-
-
80052650475
-
IL-1 blockade attenuates islet amyloid polypeptide-induced proinflammatory cytokine release and pancreatic islet graft dysfunction
-
Westwell-Roper C, Dai DL, Soukhatcheva G et al. IL-1 blockade attenuates islet amyloid polypeptide-induced proinflammatory cytokine release and pancreatic islet graft dysfunction. J Immunol 2011; 187: 2755-2765.
-
(2011)
J Immunol
, vol.187
, pp. 2755-2765
-
-
Westwell-Roper, C.1
Dai, D.L.2
Soukhatcheva, G.3
-
20
-
-
0036720342
-
Muscle-derived interleukin-6: mechanisms for activation and possible biological roles
-
Febbraio MA, Pedersen BK. Muscle-derived interleukin-6: mechanisms for activation and possible biological roles. FASEB J 2002; 16: 1335-1347.
-
(2002)
FASEB J
, vol.16
, pp. 1335-1347
-
-
Febbraio, M.A.1
Pedersen, B.K.2
-
21
-
-
81255157471
-
Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells
-
Ellingsgaard H, Hauselmann I, Schuler B et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med 2011; 17: 1481-1489.
-
(2011)
Nat Med
, vol.17
, pp. 1481-1489
-
-
Ellingsgaard, H.1
Hauselmann, I.2
Schuler, B.3
-
22
-
-
79951689303
-
Identification of autoantibody-negative autoimmune type 2 diabetic patients
-
Brooks-Worrell BM, Reichow JL, Goel A, Ismail H, Palmer JP. Identification of autoantibody-negative autoimmune type 2 diabetic patients. Diabetes Care 2011; 34: 168-173.
-
(2011)
Diabetes Care
, vol.34
, pp. 168-173
-
-
Brooks-Worrell, B.M.1
Reichow, J.L.2
Goel, A.3
Ismail, H.4
Palmer, J.P.5
-
23
-
-
33646134126
-
Effects of etanercept in patients with the metabolic syndrome
-
Bernstein LE, Berry J, Kim S, Canavan B, Grinspoon SK. Effects of etanercept in patients with the metabolic syndrome. Arch Intern Med 2006; 166: 902-908.
-
(2006)
Arch Intern Med
, vol.166
, pp. 902-908
-
-
Bernstein, L.E.1
Berry, J.2
Kim, S.3
Canavan, B.4
Grinspoon, S.K.5
-
24
-
-
27344441019
-
Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes
-
Dominguez H, Storgaard H, Rask-Madsen C et al. Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res 2005; 42: 517-525.
-
(2005)
J Vasc Res
, vol.42
, pp. 517-525
-
-
Dominguez, H.1
Storgaard, H.2
Rask-Madsen, C.3
-
25
-
-
34547099307
-
Effects of TNF-alpha neutralization on adipocytokines and skeletal muscle adiposity in the metabolic syndrome
-
Lo J, Bernstein LE, Canavan B et al. Effects of TNF-alpha neutralization on adipocytokines and skeletal muscle adiposity in the metabolic syndrome. Am J Physiol Endocrinol Metab 2007; 293: E102-109.
-
(2007)
Am J Physiol Endocrinol Metab
, vol.293
-
-
Lo, J.1
Bernstein, L.E.2
Canavan, B.3
-
26
-
-
0029906375
-
Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM
-
Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R. Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 1996; 45: 881-885.
-
(1996)
Diabetes
, vol.45
, pp. 881-885
-
-
Ofei, F.1
Hurel, S.2
Newkirk, J.3
Sopwith, M.4
Taylor, R.5
-
27
-
-
0034454915
-
No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients
-
Paquot N, Castillo MJ, Lefebvre PJ, Scheen AJ. No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients. J Clin Endocrinol Metab 2000; 85: 1316-1319.
-
(2000)
J Clin Endocrinol Metab
, vol.85
, pp. 1316-1319
-
-
Paquot, N.1
Castillo, M.J.2
Lefebvre, P.J.3
Scheen, A.J.4
-
28
-
-
34247640820
-
Insulin resistance in patients with rheumatoid arthritis: effect of anti-TNF alpha therapy
-
Rosenvinge A, Krogh-Madsen R, Baslund B, Pedersen BK. Insulin resistance in patients with rheumatoid arthritis: effect of anti-TNF alpha therapy. Scand J Rheumatol 2007; 36: 91-96.
-
(2007)
Scand J Rheumatol
, vol.36
, pp. 91-96
-
-
Rosenvinge, A.1
Krogh-Madsen, R.2
Baslund, B.3
Pedersen, B.K.4
-
29
-
-
17644393196
-
Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis
-
Kiortsis DN, Mavridis AK, Vasakos S, Nikas SN, Drosos AA. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis 2005; 64: 765-766.
-
(2005)
Ann Rheum Dis
, vol.64
, pp. 765-766
-
-
Kiortsis, D.N.1
Mavridis, A.K.2
Vasakos, S.3
Nikas, S.N.4
Drosos, A.A.5
-
30
-
-
78650917112
-
TNF-α Antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome
-
Stanley TL, Zanni MV, Johnsen S et al. TNF-α Antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome. J Clin Endocrinol Metab 2011; 96: E146-150.
-
(2011)
J Clin Endocrinol Metab
, vol.96
-
-
Stanley, T.L.1
Zanni, M.V.2
Johnsen, S.3
-
31
-
-
33746445962
-
Relapse of diabetes after interruption of chronic administration of anti-tumor necrosis factor-alpha antibody infliximab: a case observation
-
Yazdani-Biuki B, Mueller T, Brezinschek HP, Hermann J, Graninger W, Wascher TC. Relapse of diabetes after interruption of chronic administration of anti-tumor necrosis factor-alpha antibody infliximab: a case observation. Diabetes Care 2006; 29: 1712-1713.
-
(2006)
Diabetes Care
, vol.29
, pp. 1712-1713
-
-
Yazdani-Biuki, B.1
Mueller, T.2
Brezinschek, H.P.3
Hermann, J.4
Graninger, W.5
Wascher, T.C.6
-
32
-
-
4944258755
-
Improvement of insulin sensitivity in insulin resistant subjects during prolonged treatment with the anti-TNF-alpha antibody infliximab
-
Yazdani-Biuki B, Stelzl H, Brezinschek HP et al. Improvement of insulin sensitivity in insulin resistant subjects during prolonged treatment with the anti-TNF-alpha antibody infliximab. Eur J Clin Invest 2004; 34: 641-642.
-
(2004)
Eur J Clin Invest
, vol.34
, pp. 641-642
-
-
Yazdani-Biuki, B.1
Stelzl, H.2
Brezinschek, H.P.3
-
33
-
-
69549105888
-
Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes
-
Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY, Mandrup-Poulsen T. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 2009; 32: 1663-1668.
-
(2009)
Diabetes Care
, vol.32
, pp. 1663-1668
-
-
Larsen, C.M.1
Faulenbach, M.2
Vaag, A.3
Ehses, J.A.4
Donath, M.Y.5
Mandrup-Poulsen, T.6
-
34
-
-
34247170807
-
Interleukin-1-receptor antagonist in type 2 diabetes mellitus
-
Larsen CM, Faulenbach M, Vaag A et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356: 1517-1526.
-
(2007)
N Engl J Med
, vol.356
, pp. 1517-1526
-
-
Larsen, C.M.1
Faulenbach, M.2
Vaag, A.3
-
35
-
-
84864386088
-
Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes
-
Cavelti-Weder C, Babians-Brunner A, Keller C et al. Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care 2012; 35: 1654-1662.
-
(2012)
Diabetes Care
, vol.35
, pp. 1654-1662
-
-
Cavelti-Weder, C.1
Babians-Brunner, A.2
Keller, C.3
-
36
-
-
84873271227
-
Effect of anti-IL-1beta antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial
-
Rissanen A, Howard CP, Botha J, Thuren T. Effect of anti-IL-1beta antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial. Diabetes Obes Metab 2012; 14: 1088-1096.
-
(2012)
Diabetes Obes Metab
, vol.14
, pp. 1088-1096
-
-
Rissanen, A.1
Howard, C.P.2
Botha, J.3
Thuren, T.4
-
37
-
-
79960086288
-
Treatment with Anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study
-
van Asseldonk EJ, Stienstra R, Koenen TB, Joosten LA, Netea MG, Tack CJ. Treatment with Anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2011; 96: 2119-2126.
-
(2011)
J Clin Endocrinol Metab
, vol.96
, pp. 2119-2126
-
-
van Asseldonk, E.J.1
Stienstra, R.2
Koenen, T.B.3
Joosten, L.A.4
Netea, M.G.5
Tack, C.J.6
-
38
-
-
84870619337
-
Effects of interleukin-1beta inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial
-
Ridker PM, Howard CP, Walter V et al. Effects of interleukin-1beta inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation 2012; 126: 2739-2748.
-
(2012)
Circulation
, vol.126
, pp. 2739-2748
-
-
Ridker, P.M.1
Howard, C.P.2
Walter, V.3
-
39
-
-
84878774925
-
Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1beta antibody, in patients with type 2 diabetes
-
DOI: 10.2337/dc12-1835 [Epub 20 March 2013]
-
Sloan-Lancaster J, Abu-Raddad E, Polzer J et al. Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1beta antibody, in patients with type 2 diabetes. Diabetes Care 2013. DOI: 10.2337/dc12-1835 [Epub 20 March 2013].
-
(2013)
Diabetes Care
-
-
Sloan-Lancaster, J.1
Abu-Raddad, E.2
Polzer, J.3
-
40
-
-
77950885686
-
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial
-
Goldfine AB, Fonseca V, Jablonski KA, Pyle L, Staten MA, Shoelson SE. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med 2010; 152: 346-357.
-
(2010)
Ann Intern Med
, vol.152
, pp. 346-357
-
-
Goldfine, A.B.1
Fonseca, V.2
Jablonski, K.A.3
Pyle, L.4
Staten, M.A.5
Shoelson, S.E.6
-
41
-
-
64149121817
-
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes
-
Goldfine AB, Silver R, Aldhahi W et al. Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clin Transl Sci 2008; 1: 36-43.
-
(2008)
Clin Transl Sci
, vol.1
, pp. 36-43
-
-
Goldfine, A.B.1
Silver, R.2
Aldhahi, W.3
-
42
-
-
84876485218
-
A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance
-
Goldfine AB, Conlin PR, Halperin F et al. A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance. Diabetologia 2013; 56: 714-723.
-
(2013)
Diabetologia
, vol.56
, pp. 714-723
-
-
Goldfine, A.B.1
Conlin, P.R.2
Halperin, F.3
-
43
-
-
38949119419
-
Salsalate improves glycemia and inflammatory parameters in obese young adults
-
Fleischman A, Shoelson SE, Bernier R, Goldfine AB. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care 2008; 31: 289-294.
-
(2008)
Diabetes Care
, vol.31
, pp. 289-294
-
-
Fleischman, A.1
Shoelson, S.E.2
Bernier, R.3
Goldfine, A.B.4
-
44
-
-
84872018875
-
Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes
-
Lee HM, Kim JJ, Kim HJ, Shong M, Ku BJ, Jo EK. Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes. Diabetes 2013; 62: 194-204.
-
(2013)
Diabetes
, vol.62
, pp. 194-204
-
-
Lee, H.M.1
Kim, J.J.2
Kim, H.J.3
Shong, M.4
Ku, B.J.5
Jo, E.K.6
-
45
-
-
77957652845
-
Inhibition of dipeptidyl peptidase 4 regulates microvascular endothelial growth induced by inflammatory cytokines
-
Takasawa W, Ohnuma K, Hatano R, Endo Y, Dang NH, Morimoto C. Inhibition of dipeptidyl peptidase 4 regulates microvascular endothelial growth induced by inflammatory cytokines. Biochem Biophys Res Commun 2010; 401: 7-12.
-
(2010)
Biochem Biophys Res Commun
, vol.401
, pp. 7-12
-
-
Takasawa, W.1
Ohnuma, K.2
Hatano, R.3
Endo, Y.4
Dang, N.H.5
Morimoto, C.6
|